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Abstract
Introduction
To  make  recommendations  for  future  clinical,  public 
health, and research practices for women with abnormal 
glucose tolerance during pregnancy, we reviewed the latest 
evidence regarding rates of postpartum diabetes screening 
and types of screening tests.
Methods
We searched PubMed for journal articles published from 
January 2008 through December 2010 that reported on 
postpartum screening and studies designed to prevent pro-
gression to type 2 diabetes among women with gestational 
diabetes  mellitus  (GDM).  Two  authors  independently 
reviewed titles and abstracts from 265 articles.
Results
From 34% to 73% of women with GDM completed post-
partum glucose screening. Predictors of higher screening 
rates included older age, nulliparity, and higher income or 
education. Screening rates varied by race/ethnicity; Asian 
women were more likely to be screened than were other 
racial/ethnic  minorities.  Women  who  received  prenatal 
care,  who  were  treated  with  insulin  during  pregnancy, 
or  who  completed  a  6-week  postpartum  visit  were  also 
more likely to receive screening. A moderate proportion 
of  women  screened  had  type  2  diabetes  (1.2%-4.5%)  or   
prediabetes (12.2%-36.0%).
Conclusion
Rates of postpartum screening among women with a his-
tory of GDM are low; only half of women in most popula-
tions are screened. Our findings can inform future screen-
ing initiatives designed to overcome barriers to screening 
for  both  providers  and  patients.  Well-designed  lifestyle 
interventions specific to women with a history of abnormal 
glucose  tolerance  during  pregnancy  and  also  studies  to 
determine the efficacy and safety of pharmacological inter-
ventions will be important to help prevent progression to 
diabetes among these high-risk women.
Introduction
Type  2  diabetes  mellitus,  a  global  epidemic,  affects 
approximately 21 million people in the United States (1). 
According to the 2005-2006 National Health and Nutrition 
Examination Survey (NHANES), the standardized total 
diabetes  prevalence  was  17.4%  among  both  men  and 
women, which reflects an absolute increase from the 1988-
1994 NHANES of 3.7% among women compared with 2.1% 
among men (2). During this period, the number of women 
with undiagnosed type 2 diabetes increased, whereas the 
number  of  men  with  undiagnosed  diabetes  decreased. 
Given the damaging effect of prolonged undetected hyper-
glycemia, prevention and early diagnosis of type 2 diabetes 
is cost-saving and of public health importance (3).
Diagnosis  of  both  gestational  diabetes  mellitus  (GDM) 
and milder abnormal glucose tolerance in pregnancy helps 
health care professionals identify women who are at high 
risk for type 2 diabetes (4-7). GDM confers a 7-fold risk for 
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future type 2 diabetes (8), and up to one-third of women 
with type 2 diabetes have been diagnosed with GDM (9). 
Although recommendations for postpartum screening of 
women with a history of GDM exist (3,10), many women 
are not screened. Furthermore, the most appropriate type 
and frequency of screening has recently been the subject of 
active discussion and investigation (11-13).
This article is part of the “Best Practices for Screening 
Reproductive  Aged  Women  for  Chronic  Disease  and 
Related  Risk  Factors”  special  collection  in  this  issue  of 
Preventing Chronic Disease. We review the latest evidence 
regarding postpartum screening rates and results among 
women with a history of GDM and also discuss findings 
from observational studies and randomized trials designed 
to prevent progression to type 2 diabetes among postpar-
tum women with a history of GDM. In addition, we make 
recommendations  for  future  clinical,  public  health,  and 
research practice.
Methods
Data sources
To review postpartum screening rates and studies designed 
to prevent progression to type 2 diabetes among women 
with a history of GDM, we searched published journal arti-
cles in English from January 1, 2008, through December 
31,  2010.  We  focused  on  the  most  recent  literature  to 
augment and update other recent reviews. We searched 
PubMed  by  using  the  search  terms  1)  “gestational  dia-
betes”  and  “postpartum”  or  2)  or  “gestational  diabetes” 
and “follow-up.” We also included additional articles that 
we identified by reviewing reference lists of studies and 
review articles.
Study selection and data extraction
Our initial search returned 265 articles. Two authors (A.T. 
and E.O.) independently reviewed titles and abstracts and 
obtained all potential articles for additional review; they 
also conducted all data abstraction and reached consensus 
through discussion about any disagreement. Articles that 
were  deemed  irrelevant  and  excluded  from  the  review 
were  related  to  screening  for  GDM  during  pregnancy 
only,  screening  for  metabolic  syndrome  or  cardiovascu-
lar  disease,  or  maternal  or  infant  outcomes  associated 
with  GDM,  type  1  diabetes,  obesity  during  pregnancy, 
fertility and obstetric complications, interventions during   
pregnancy  to  improve  GDM  or  improve  pregnancy  out-
comes  for  mother  or  infant,  or  articles  related  to  other 
diseases during pregnancy such as preeclampsia or poly-
cystic ovary syndrome. Relevant articles reported on the 
following topics: 1) recommendations for types of screen-
ing tests, 2) rates and results of diabetes screening among 
women  with  prior  GDM  diagnosis  at  any  time  period 
postpartum, 3) results and comparisons of different types 
of screening tests, 4) predictors of and barriers to screen-
ing, and 5) interventions to improve rates of postpartum 
diabetes  screening.  We  identified  11  published  studies 
that evaluated rates and results of postpartum screening 
for diabetes among women with GDM (1-3) and 21 stud-
ies that discussed predictors of and barriers to screening 
or interventions to improve rates of postpartum diabetes 
screening (4,5). We discuss findings for the first postpar-
tum year and the later postpartum period separately.
Results
Postpartum screening for type 2 diabetes among women 
with GDM
Both  the  American  College  of  Obstetricians  and 
Gynecologists (10) and the American Diabetes Association 
(3,14)  recommend  that  women  whose  pregnancy  was 
complicated by GDM be screened for persistent glucose 
abnormality at 6 to 12 weeks postpartum with either a 
fasting plasma glucose (FPG) test alone or with a fast-
ing 75-g, 2-hour oral glucose tolerance test (OGTT). The 
OGTT  is  more  sensitive,  with  reported  sensitivities  of 
100%  compared  with  67%  for  FPG.  The  FPG  test  may 
be  more  acceptable  to  women  because  it  requires  less 
time, which could help overcome attrition in attendance 
for repeated follow-up testing in addition to being more 
easily tolerated (13,15). Criteria for diagnosing diabetes 
postpartum via a 75-g OGTT are similar to those for non-
pregnant adult women (3), and thus results can identify 
overt  diabetes  mellitus,  impaired  fasting  glucose  (IFG), 
impaired  glucose  tolerance  (IGT),  or  normal  glycemia; 
however, the FPG test can identify IFG but not IGT. Both 
the American College of Obstetricians and Gynecologists 
and the American Diabetes Association recommend that 
women with a history of GDM with a normal postpartum 
screening be rescreened every 3 years, and women with 
IFG  or  IGT  or  both  (prediabetes)  should  be  rescreened 
annually. Recent consensus guidelines recommend follow-
up testing with an OGTT at 1 year postpartum, FPG test 
yearly, and consideration of an OGTT at 3 years (16).VOLUME 8: NO. 6
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Rates and results of postpartum screening for type 2 dia-
betes mellitus
We identified 11 studies published from 2008 through 2010 
(17-27) that evaluated rates of postpartum screening for 
diabetes among women with GDM; of those, 8 were based 
on review of medical records and 3 were based on mailed 
questionnaires or interviews (Table). Together, these stud-
ies included 32,240 women with pregnancies complicated 
by GDM from 1999 through 2008. Postpartum diabetes 
screening  rates  varied  but  were  generally  poor:  34%  to 
73% (median, 48%) of women overall were screened.
Three  of  these  studies  included  large,  diverse  popula-
tions  of  women  receiving  care  at  health  maintenance 
organizations (HMOs) in California and Oregon affiliated 
with Kaiser Permanente. All 3 studies demonstrated sub-
stantial increases in screening during recent years. For 
example, among 14,448 women with GDM who received 
care  at  Kaiser  Permanente  Northern  California,  rates 
of postpartum screening increased from 20% in 1995 to 
56% in 2006 (18). Even in the most recent years, however, 
fewer than 60% of women were screened. In 5 studies 
of  smaller  populations  seen  at  referral  centers  in  the 
United States (San Francisco, Texas), Canada, Poland, 
and Turkey, screening rates were similar (33.7%, 57.0%, 
48.2%, 37.2%, and 47.4%, respectively) (17,22,23,26,27). 
Morrison et al surveyed Australian women whose mean 
(SD)  duration  since  delivery  was  21.2  (8.4)  months. 
Respondents  reported  a  higher  overall  screening  rate 
of  73.2%,  although  only  27.3%  reported  having  been 
screened according to Australian Diabetes in Pregnancy 
Society  guidelines  (a  75-g  OGTT  administered  6  to  8 
weeks postdelivery) (24).
Although the recommended timing of screening is 6 to 
12 weeks postpartum, all but 1 of the studies included 
longer  follow-up  (18).  However,  screening  rates  were 
not  markedly  improved  when  the  time  window  was 
broader.  For  example  in  2006,  screening  rates  were 
50.3% in a study within 3 months of postpartum follow-
up (20), 48.2% to 51.0% in 2 studies within 6 months 
of postpartum follow-up (19,22), and 55.9% in a study 
within 12 months of postpartum follow-up (18). Among 
women  seen  at  Kaiser  Southern  California  who  were 
screened  within 6  months,  41%  were  screened  from  7 
days through 6 weeks postpartum, 46% from 6 through 
12 weeks postpartum, and 12% from 12 weeks through 6 
months postpartum (19).
The type of screening tests included and results varied 
across the studies. Ogonowski and Miazgowski and Swan 
et  al  included  only  OGTT  (23,25).  The  other  9  studies 
included either FPG or OGTT (17-22,24,26,27) although, of 
these, 2 did not report percentages of women screened with 
each test (17,21). In 4 studies, 79% to 100% of women were 
screened with FPG (18-20,27), whereas in the remaining 3 
studies, most women (56%-95%) were screened with OGTT 
(22,24,26) (Table). A number of women screened postpar-
tum were found to have type 2 diabetes (1.2%-4.5%) or 
prediabetes (12.2%-36%) (Table). In Turkey, Kerimoglu et 
al reported that 50% (5 of 10) of the patients who received 
an OGTT and 7.4% (2 of 27) of the patients who received 
FPG were diagnosed with type 2 diabetes (27). Other stud-
ies have found that up to one-third of women with GDM 
will have abnormal postpartum screening (diabetes, IFG, 
or IGT) (28,29). According to Kwong et al, using only FPG 
in postpartum screening would cause up to 75% of women 
with IGT or type 2 diabetes to be missed (22). Similarly, 
Hunt  et  al  found  that  of  the  women  with  postpartum 
OGTT  with  IGT,  approximately  one-third  had  outside 
range values on the 2-hour value alone (26). These find-
ings  are  consistent  with  a  substantial  literature  that  a 
single FPG has a sensitivity of 16% to 89% when compared 
with an OGTT (13,15,30).
Three studies of postpartum screening rates used differ-
ent methods and did not include test results. Almario et al 
identified women with GDM by using laboratory data from 
a university teaching hospital and found that only one-
third of medical records included plans to perform postpar-
tum screening (21). Morrison et al mailed questionnaires 
to Australian postpartum women with a history of GDM 
and found a higher rate of self-reported screening at any 
time (73.2%) compared with the 38%-45% elsewhere at the 
time of the study, although many fewer women (27.3%) 
received an OGTT within 6 to 8 weeks postpartum as per 
Australian recommendations (24). Another survey of 77 
Australian women with a GDM pregnancy found that 61% 
self-reported postpartum diabetes screening (25).
Factors associated with likelihood of postpartum diabetes 
screening
Rates  of  diabetes  screening  among  postpartum  women 
with  a  history  of  GDM  differed  by  race  and  ethnicity, 
although findings varied (Table). For example, Stasenko 
et al found that Hispanic women had the lowest follow-up 
frequency (18% compared with 28% of white women and 
29% of African American women) (17), whereas Lawrence VOLUME 8: NO. 6
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et al found Hispanic women in another population were 
more likely to be screened (51% vs 48% of white women 
and 27% of African American women) (19). Asian women 
were  most  likely  to  be  screened  compared  with  women 
of other racial and ethnic backgrounds (odds ratio, 1.4; 
95%  confidence  interval,  1.2-1.5)  (18,19).  Other  patient 
characteristics  associated  with  higher  rates  of  postpar-
tum screening included older age, nulliparity, and higher 
income or education. Women who received prenatal care, 
were treated with insulin during pregnancy, or completed 
a 6-week postpartum visit were also more likely to receive 
a postpartum diabetes screening (Table).
Of the 21 additional studies identified, 3 discussed bar-
riers  to  postpartum  screening  (31-33).  Barriers  to  post-
partum screening included provider, patient, and system-
level  issues.  In  surveys  of  providers  in  Massachusetts, 
North Carolina, and Canada, providers commonly identi-
fied lack of patient attendance at a postpartum visit as 
the primary reason for not completing postpartum screen-
ing (31,32). However, in a chart review of data from 197 
Massachusetts  women  with  pregnancies  complicated  by 
GDM from 2000 through 2001, Smirnakis et al found that 
94%  of  the  women  completed  postpartum  Papanicolaou 
screening, whereas 67% received any postpartum glucose 
testing and only 37% had an FPG or OGTT (34). Other 
barriers to postpartum screening identified by clinicians 
included 1) clinicans’ perception that screening guidelines 
were “inconsistent,” 2) patient cost or inconvenience (31), 
3) lack of documentation of GDM on problem lists, and 4) 
poor  communication  between  obstetricians  and  primary 
care providers (33). Patients identified time pressure as a 
primary barrier (32).
Postpartum  reminders  may  help  to  improve  diabetes 
screening  rates.  In  a  randomized  trial  of  223  women, 
mailed  reminders  resulted  in  improved  screening  rates 
within  12  months  postpartum  when  sent  to  physicians 
only (52%), patients only (55%), or both (61%), compared 
with no reminders (14%) (35). However, only 48% of women 
seen at a Canadian diabetes referral clinic completed post-
partum  glycemic  screening,  even  though  women  were 
given laboratory requisitions before delivery and received 
a telephone reminder if testing was not completed by 6 
months postpartum (22). Ferrara et al reported that the 
proportion of women receiving an OGTT increased from 
17% in 2005 to 72% in 2006, when Kaiser Permanente 
Northern  California  instituted  a  nurse-managed  care 
program  that  included  greater  attention  to  postpartum 
screening guidelines (18).
Factors associated with increased likelihood of abnormal 
postpartum screening test results
Women who have a family history of diabetes, are from 
a  high-risk  racial/ethnic  group  (eg,  South  Asian),  have 
a  higher  prepregnancy  or  postpartum  body  mass  index 
(BMI)  (>25  kg/m2),  have  a  higher  glucose  or  greater 
number  of  abnormal  glucose  values  on  prenatal  glyce-
mic screening, who are diagnosed with GDM earlier in 
pregnancy, or who require insulin during pregnancy are 
more  likely  to  have  prediabetes  or  type  2  diabetes  on 
postpartum screening (7,13,28,36-41). Fewer studies have 
examined  potentially  modifiable  characteristics  such  as 
maternal diet (total energy intake, fat intake), physical 
activity, and breastfeeding (37), but these studies suggest 
that certain dietary patterns may play a role in increasing 
risk for developing type 2 diabetes.
Diabetes screening after the early postpartum period
Risks for abnormal glycemia persist even after the early 
postpartum period. In a study by Retnakaran et al, among 
70  women  with  GDM  but  normal  OGTT  at  3  months 
postpartum,  17%  had  prediabetes  (IFG,  IGT,  or  both) 
when reevaluated with OGTT at 12 months postpartum, 
compared with 3% of 73 women with normal glucose toler-
ance both during pregnancy and at 3 months postpartum 
(4). Even women with lesser degrees of abnormal glucose 
during pregnancy were at elevated risk for abnormal 12-
month OGTT despite a normal 3-month OGTT (39). Risk 
factors for abnormal 12-month screening included higher 
3-month postpartum glucose, BMI, low density lipoprotein 
cholesterol, triglycerides, and leptin, and lower high den-
sity lipoprotein cholesterol and adiponectin (4).
Risks for prediabetes, type 2 diabetes, and metabolic syn-
drome  continue  to  increase  over  time,  since  pregnancy. 
Recent  studies  found  that  16%  to  30%  of  women  with 
GDM develop type 2 diabetes by 5 to 10 years postpartum 
(42-44), and more cases accumulate even later. In a 2009 
meta-analysis of 20 studies that included 675,455 women 
and 10,859 type 2 diabetes events, women with a GDM 
pregnancy had a nearly 7.5-fold increased risk of develop-
ing diabetes (8). Within 5 years of a pregnancy complicated 
by GDM, women had a relative risk of 4.7, which increased 
to  9.3  in  those  who  were  examined  more  than  5  years 
postpartum. In a 2010 population-based cohort study of 
more than 6,000 women from northern Finland followed 
since their pregnancies in 1986, the cumulative incidence 
of diabetes continued to increase even at 20 years postpar-VOLUME 8: NO. 6
NOVEMBER 2011
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tum. Rates were particularly high among women with a   
history  of  GDM  who  were  overweight  (26%),  compared 
with controls who had no risk factors for GDM (0.7%) (45). 
Risk  factors  for  late  progression  to  type  2  diabetes  are 
similar to risk factors for early progression and include 
low insulin sensitivity, insulin resistance and progressive 
insulin secretory defect, and gain in weight and body fat.
Although  we  identified  several  recent  screening  studies 
completed within the first postpartum year, we found no 
recent studies that evaluated rates of diabetes screening 
in clinical settings after this time period. We found only 1 
published intervention to promote longer-term follow-up of 
women with a history of GDM; in South Australia begin-
ning in 2002, women with GDM were invited to provide 
contact information to a GDM registry, which then sent 
women annual mailed reminders for glycemic screening 
and requests for diabetes screening updates beginning at 
15 months postpartum (46). Findings suggest that these 
reminders helped promote screening. While 56% of women 
reported glycemic screening in the first postpartum year 
(before the intervention began), 75% reported having been 
screened  during  the  second  postpartum  year.  However, 
fewer than half of eligible women responded to the update 
requests, and thus reporting bias was likely.
Discussion
Because the prevalence of type 2 diabetes is increasing 
among all groups in the United States and undiagnosed 
cases  are  particularly  high  among  women,  prevention 
and  early  diagnosis  of  type  2  diabetes  have  become 
public  health  priorities.  A  diagnosis  of  GDM  identifies 
women who are at high risk for developing type 2 dia-
betes. We found that even recent studies published from 
2008 through 2010 documented poor rates of postpartum 
screening  for  diabetes  among  women  with  pregnancies 
complicated by GDM.
Most of the studies we reviewed included follow-up periods 
longer than the recommended 6 to 12 weeks postpartum. 
Nevertheless,  screening  rates  were  low.  This  finding 
coincides with results from other studies, which suggest 
that some barriers to screening (eg, lack of patient atten-
dance, inconsistency of screening guidelines, patient cost 
or inconvenience [31], and poor communication between 
obstetricians and primary care providers [33]) may per-
sist beyond the recommended screening timeframe. Since 
risks for abnormal glycemia persist even after the early 
postpartum period (4,39), ongoing screening is required for 
women with a history of GDM every 1 to 3 years depend-
ing on the results of the postpartum screen and the likeli-
hood of a future pregnancy. Although we found no recent 
studies that evaluated clinical screening for diabetes after 
the first postpartum year, rates of screening over the long 
term are probably even lower than during the early post-
partum period. Further studies will be needed to evaluate 
the  prevalence,  predictors,  and  outcomes  of  long-term 
screening.
According to Lawrence et al, Kwong et al, and Hunt and 
Conway, many women with IGT or type 2 diabetes were 
likely missed when women were screened by using only an 
FPG test (19,22,26). This finding is consistent with earlier 
studies that found that the FPG test alone has poor sensi-
tivity for diagnosis of prediabetes and type 2 diabetes com-
pared with OGTT (30); however, its greater convenience 
may result in higher screening rates (47). Nevertheless, in 
2007, Kim et al simulated postpartum screening for diabe-
tes with FPG, OGTT, and hemoglobin A1c annually, every 
2 years, and every 3 years over a period of 12 years, and 
found that OGTTs resulted in lower costs per case detected 
than FPG or hemoglobin A1c testing (48). More recently, 
the American Diabetes Association has allowed for the use 
of hemoglobin A1c as a screening test among the general 
population at risk for diabetes (3). Whether this test will 
be recommended for early postpartum screening remains 
unclear, but further research in this area is needed as the 
convenience and low participant burden of the hemoglobin 
A1c has the potential to increase screening rates.
Our  review  confirms  that  type  2  diabetes  is  common 
among  postpartum  women  with  a  history  of  GDM  and 
that screening is acceptable to many women. According 
to  previous  studies,  screening  is  appropriate  only  if  an 
effective  intervention  exists  and  if  early  identification 
and treatment result in improved outcomes (49). Findings 
from  intervention  studies,  most  notably  the  Diabetes 
Prevention Program (DPP), provide evidence that lifestyle 
changes or pharmacotherapy can prevent the onset of type 
2 diabetes among women with a history of GDM who have 
abnormal test results (IFG or IGT) on postpartum screen-
ing (50-56). However, the lifestyle intervention in the DPP 
was intensive and expensive, limiting its generalizability. 
Additionally, women with a GDM history entered the DPP 
an average of 12 years postpartum. Given the demands 
of parenting an infant, it is likely that few women in the 
early postpartum period could engage in such an intensive 
program, yet early interventions are important. The first VOLUME 8: NO. 6
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few postpartum years represent a particularly high-risk 
period for development of prediabetes or type 2 diabetes.
Randomized controlled trials of postpartum lifestyle inter-
ventions  have  not  targeted  women  with  GDM  in  par-
ticular, yet a recent systematic review found that 6 of 8 
lifestyle  interventions  were  effective  at  promoting  post-
partum  weight  loss  (57).  Recent  studies  (25,33,58)  sug-
gest that ample opportunity exists to improve weight and 
related lifestyle behaviors among postpartum women with 
a history of GDM. In addition to the traditional behavior 
change targets of diet and physical activity, observational 
studies  suggest  that  breastfeeding,  adequate  sleep,  and 
avoidance of television viewing may also help minimize 
postpartum weight retention and diabetes risk (59-62).
We identified no studies of postpartum screening for dia-
betes among women with GDM that also included infor-
mation on prepregnancy or early pregnancy glycemic sta-
tus. Whereas historically GDM has been defined as “any 
degree of glucose intolerance with onset or first recognition 
during pregnancy” (63), more recently it has been recog-
nized that this definition includes a spectrum of glycemia 
entering pregnancy, including women with pregestational 
prediabetes or type 2 diabetes and also those with tran-
sient abnormal glucose levels that resolve after delivery. 
As more women become pregnant at older ages and with 
higher weights, a fraction of women diagnosed with GDM 
may actually have undiagnosed prediabetes or overt type 
2 diabetes (64-66). Even women with abnormal glucose 
levels during pregnancy that do not meet criteria for GDM 
are at increased risk for postpartum prediabetes and type 
2 diabetes (7,36). Recent consensus guidelines recommend 
first-trimester  screening  among  women  at  high  risk  as 
well as thresholds that allow for diagnosis of overt diabe-
tes at the time of early third trimester screening, which 
will identify women who merit especially close postpartum 
follow-up (67). As of 2011, these guidelines are endorsed 
by the American Diabetes Association (14). Future studies 
with information on women’s glycemic status throughout 
the reproductive years will be invaluable in understand-
ing the effect of abnormal glucose on outcomes during and 
after pregnancy.
There were several limitations to this systematic review. 
Because most of these studies were conducted within a 
large  HMO  system,  where  structural  interventions  for 
follow-up are often in place, or in diabetes referral clinic 
populations,  postpartum  screening  rates  are  probably 
even lower among the general population. Also, 2 of the 
identified  studies  that  reported  higher  screening  rates 
were completed in Australia, a country with a different 
health care system from that of the United States. Newly 
recommended  guidelines  for  GDM  diagnosis  will  iden-
tify a much larger number of US women, perhaps 1 in 5 
pregnant women, who will require treatment during preg-
nancy and screening postpartum (67). Future research is 
needed to assess the success of structural interventions in 
increasing postpartum screening rates in settings other 
than large HMOs, and also other intervention strategies 
such as those delivered directly to women via Internet, 
cell  phone,  or  other  technologies.  Proven,  cost-effective, 
and readily generalizable strategies to promote both early 
and ongoing postpartum diabetes screening among women 
with a history of GDM are greatly needed.
In  conclusion,  as  rates  of  type  2  diabetes  continue  to 
increase,  especially  among  women,  more  prevention 
opportunities are needed. Among women who experience 
glucose abnormalities during pregnancy, screening during 
the postpartum period offers a window of opportunity for 
early identification of diabetes and prediabetes. Although 
rates  of  screening  have  increased  during  the  past  sev-
eral decades, these rates are still not optimal and need 
to increase, given the type 2 diabetes epidemic faced by 
both developed and developing nations. Increasing rates 
of screening may be challenging; different players (health 
care  providers  and  public  health  workers)  need  to  be 
involved. Future work should focus on reducing barriers 
to  screening  for  both  providers  and  patients.  Lifestyle 
interventions specific to women with history of GDM are 
needed, as are studies to determine the efficacy and safety 
of pharmacological interventions among women of child-
bearing age.
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Table
Table. Studies of Postpartum Screening for Diabetes Among Women With a History of Gestational Diabetes Mellitus (GDM), 
Published 2008-2010
Reference Study Design and Setting Women Screened, % Type of Screening, Results Predictors of Screening
Kerimoğlu et al, 2010 (27) Telephone interview, n = 
78 (of 335), identified from 
retrospective chart review 
Etlik, and Ankara, Turkey, 
200-200
Overall, 4.4. FPG (73%) or IGT (27%).
Up to 12 wks postpartum. 
Results of OGTT: 50% T2DM, 
20% IFG/IGT. Results of 
FPG: 7.4% T2DM, 40.7% 
IFG/IGT.
Insulin treatment during 
pregnancy and higher edu-
cation (for OGTT screening 
only).
Swan et al, 2010 (25) Mailed questionnaires, n = 
84 (of 210), identified from 
regional referral hospitals 
medical record database 
in Victoria, Australia, 2001-
200
Overall, 61.0. OGTT Women living in small rural 
areas.
Stasenko et al, 2010 (17) Retrospective chart review, 
n = 4, academic medical 
center, 2002-2008
Overall, 33..
White, 2.; African 
American, 28.6; Hispanic/
Latina, 1.8; Asian, 43.2.
FPG or OGTT (% not report-
ed), 0-6 mos postpartum; 
results: 2.0% T2DM, 28.3% 
IFG/IGT.
Older age, nulliparity, insulin 
requirement during preg-
nancy.
Lawrence et al, 2010 (19) Retrospective chart review, 
n = 11,82, HMO, 1-
2006
Overall, 0.2.
1: 34.4; 2006: 1.0.
White, 4.; Black, 2.2; 
Hispanic/Latina, 1.1; 
Asian, .0; Other/
Unknown, 4.8.
FPG (79.1%) or OGTT 
(18.2%), both (2.7%).
 d-6 mos postpartum.
Results overall: 1.1% T2DM, 
16.3% IFG/IGT. Results of 
OGTT: 2.3% T2DM, 27.6% 
IFG/IGT.
Older age, higher income, 
higher education, foreign-
born, lower parity, vaginal 
delivery, nonmacrosomic 
infant, having a postpartum 
visit, having GDM coded 
diagnosis code, receiving no 
therapy or insulin (vs oral 
therapy alone).
Ferrara et al, 2009 (18) Retrospective chart review, 
n = 14,448, HMO, 1-
2006
Overall, 38.2.
1: 20.3; 2006: ..
White, 33.2; Asian, 4.; 
Hispanic, 40.; African 
American, 26.1; Other/
Unknown, 34.1.
FPG or OGTT (1995, 5%; 
2006, 71.5%).
6 wks-1 y postpartum.
2006 results: 2.7% T2DM, 
31.3% IFG/IGT.
Older age, not being obese, 
lower parity, higher educa-
tion, GDM diagnosis earlier 
in pregnancy, use of dia-
betes medications during 
pregnancy, more provider 
contacts after delivery.
Kwong et al, 2009 (22) Retrospective chart review, 
n = 0, gestational diabe-
tes clinic in Canada, 1-
2006
Overall, 48.2. 
Caucasian, 46.; Non-
Caucasian, 0.1.
FPG (4.8%) or OGTT (95.2%).
6 wks-6 mos postpartum.
Results: 3.2% T2DM, 17.0% 
IFG/IGT.
Older age, lower parity, and 
insulin use during preg-
nancy.
 
Abbreviations: FPG, fasting plasma glucose; IGT, impaired glucose tolerance; OGTT, 2-hour, -g oral glucose tolerance test; T2DM, type 2 diabetes mellitus; 
IFG, impaired fasting glucose; HMO, health maintenance organization; NA, not applicable; DM, diabetes mellitus.
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Reference Study Design and Setting Women Screened, % Type of Screening, Results Predictors of Screening
Morrison et al, 2009 (24) Mailed questionnaires, n = 
1,372 (of 15,893), women 
registered with Australian 
National Diabetes Service 
Scheme, 2003-200
Any screening, 3.2. Any 
screen 6-8 wks: 60.. OGTT 
at 6-8 wks: 2.3.
FPG (32.6%), OGTT (56.4%).
Any and within recommend-
ed 6-8 wks postpartum.
Results not reported.
NA
Ogonowski and Miazgowski, 
2009 (23)
Retrospective chart review, 
n = 8, diabetes clinic pop-
ulation, Poland, 200-200
Overall, 3.2. OGTT 
- wks postpartum.
Results: 1.3% T2DM, 12.2% 
IFT/IGT.
Older age, insulin require-
ment in pregnancy.
Dietz et al, 2008 (20) Retrospective chart review, 
HMO population, n = 1,12 
with confirmed GDM, 1-
2006
Overall, not reported. 
1: ; 2006: 0.3.
FPG 100%, OGTT 0%.
0-3 mos postpartum.
Results: 2.1% T2DM, 10.7% 
IFG.
NA
Almario et al, 2008 (21) Retrospective review of 
laboratory records, university 
hospital, n = 0, 2004-2006
Screening tests ordered, 
20.0. 
Screening test ordered or 
referred elsewhere for test-
ing, 33.3.
FPG or OGTT (% not report-
ed) 
-12 wks postpartum.
Results not reported.
GDM diagnosis <24 wks 
gestation, GCT result >10 
mg/dL, treatment of GDM 
with insulin or glyburide, 
family history of DM.
Hunt and Conway, 2008 
(26)
Prospective cohort of pre-
dominantly Mexican or 
Mexican American women, n 
= 0, University Hospital of 
San Antonio, 2001-2003
Overall, . FPG (28%) or OGTT (72%).
4-12 wks postpartum. 
Results: 4.5% T2DM, 36% 
IFG/IGT.
Less likely to have had GDM, 
lower prepregnancy weight, 
lower point estimates for all 
glucose levels at diagnosis 
of GDM, nonuse of insulin or 
medications and more con-
trol over GDM.
 
Abbreviations: FPG, fasting plasma glucose; IGT, impaired glucose tolerance; OGTT, 2-hour, -g oral glucose tolerance test; T2DM, type 2 diabetes mellitus; 
IFG, impaired fasting glucose; HMO, health maintenance organization; NA, not applicable; DM, diabetes mellitus.
Table. (continued) Studies of Postpartum Screening for Diabetes Among Women With a History of Gestational Diabetes Mellitus 
(GDM), Published 2008-2010